Oncotarget

Research Papers:

Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma

Jiao Ma, Wei Xing, Greg Coffey, Karen Dresser, Kellie Lu, Ailin Guo, Gordana Raca, Anjali Pandey, Pamela Conley, Hongbo Yu and Lynn Y. Wang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:43881-43896. https://doi.org/10.18632/oncotarget.6316

Metrics: PDF 1280 views  |   HTML 1877 views  |   ?  


Abstract

Jiao Ma1, Wei Xing2, Greg Coffey3, Karen Dresser2, Kellie Lu4, Ailin Guo5, Gordana Raca6, Anjali Pandey3, Pamela Conley3, Hongbo Yu2, Y. Lynn Wang5

1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA

2Department of Pathology, University of Massachusetts Memorial Medical Center and Medical School, Worcester, MA, USA

3Department of Biology, Portola Pharmaceuticals, Inc., South San Francisco, CA, USA

4University of Chicago Laboratory School, Chicago, IL, USA

5Department of Pathology, Division of Genomic and Molecular Pathology, University of Chicago, Chicago, IL, USA

6Department of Medicine, University of Chicago, IL, USA

Correspondence to:

Y. Lynn Wang, e-mail: ylwang@bsd.uchicago.edu

Keywords: diffuse large B cell lymphoma, cerdulatinib, SYK, JAK-STAT, molecularly targeted therapy

Received: May 27, 2015     Accepted: October 23, 2015     Published: November 05, 2015

ABSTRACT

B-cell receptor (BCR) and JAK/STAT pathways play critical roles in diffuse large B-cell lymphoma (DLBCL). Herein, we investigated the anti-lymphoma activity of cerdulatinib, a novel compound that dually targets SYK and JAK/STAT pathways. On a tissue microarray of 62 primary DLBCL tumors, 58% expressed either phosphorylated SYK or STAT3 or both. SYK and STAT3 are also phosphorylated in a panel of eleven DLBCL cell lines although ABC and GCB subtypes exhibited different JAK/STAT and BCR signaling profiles. In both ABC and GCB cell lines, cerdulatinib induced apoptosis that was associated with caspase-3 and PARP cleavage. The compound also blocked G1/S transition and caused cell cycle arrest, accompanied by inhibition of RB phosphorylation and down-regulation of cyclin E. Phosphorylation of BCR components and STAT3 was sensitive to cerdulatinib in both ABC and GCB cell lines under stimulated conditions. Importantly, JAK/STAT and BCR signaling can be blocked by cerdulatinib in primary GCB and non-GCB DLBCL tumor cells that were accompanied by cell death. Our work provides mechanistic insights into the actions of cerdulatinib, suggesting that the drug has a broad anti-tumor activity in both ABC and GCB DLBCL, at least in part by inhibiting SYK and JAK pathways.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6316